GELS vs IFF vs OGN Stock Comparison

Gelteq, International Flavors & Fragrances and Organon Prices as of Oct 27, 2026 Peers: Industry group
GELS Gelteq Ltd
$0.46 -16.4% 1M -62.0% 1Y
Market cap
$4.93M
P/E
–
Revenue (TTM)
—
Div. yield
–
Contract Manufacturing Healthcare
OGN Organon & Co.
$13.74 +0.1% 1M +94.6% 1Y
Market cap
$3.61B
P/E
17.3x
Revenue (TTM)
$6.13B
Div. yield
0.58%
Pharmaceuticals Healthcare
6 wins

Head to Head

12 decided of 12

International Flavors & Fragrances leads on 6 of the 12 questions below (International Flavors & Fragrances 6, Organon 6). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGELSIFFOGNLeader
Larger companyMarket capitalisation $4.93M $23.80B $3.61B IFF
Cheaper on earningsLower P/E, profitable companies only — 34.2x 17.3x OGN
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 28.4x 3.9x OGN
Faster revenue growthRevenue growth, trailing twelve months — -4.6% -2.5% OGN
More profitableNet margin, trailing twelve months — 7.0% 3.4% IFF
Better return on capitalReturn on invested capital — 3.0% 5.0% OGN
Less leveragedLower net debt / EBITDA — 3.0x 5.0x IFF
Higher dividend yieldTrailing dividend yield — 1.72% 0.58% IFF
Better 1-year returnPrice return, last 12 months -62.0% +42.8% +94.6% OGN
Better 5-year returnAnnualised price return, 5 years — -8.9%/yr -17.8%/yr IFF
Less volatileAnnualised volatility, 1 year 159.5% 35.0% 56.8% IFF
Higher overall scoreMean of the five percentile scores vs peers — 51/100 55/100 OGN

Percentile Scorecard

GELSIFFOGN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGELSIFFOGN
Valuation – 43 #54 of 94 99 #9 of 625
Growth – 82 #17 of 91 23 #462 of 602
Profitability – 59 #36 of 86 88 #68 of 551
Financial Health 67 #5 of 13 46 #52 of 95 17 #547 of 656
Shareholder Returns – 28 #51 of 70 50 #182 of 365
Overall – 51 55
  • GELS ranked among 13 companies in Pharma Services
  • IFF ranked among 99 companies in Chemicals
  • OGN ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGELSIFFOGNSPY
1 month -16.4%+8.8%+0.1% -0.2%
3 months -22.0%+17.7%+1.6% +3.9%
6 months -31.3%+31.8%+3.2% +8.2%
Year to date -42.5%+38.4%+91.6% +12.9%
1 year -62.0%+42.8%+94.6% +12.3%
3 years —+37.4%-8.2% +87.4%
3 years, per year —+11.2%-2.8% +23.3%
5 years —-37.2%-62.4% +67.9%
5 years, per year —-8.9%-17.8% +10.9%
10 years —-30.1%— +261.1%
10 years, per year —-3.5%— +13.7%

Risk

MeasureGELSIFFOGNSPY
Volatility, 1Y 159.5%35.0%56.8% 12.7%
Downside volatility, 1Y 122.0%28.6%39.3% 12.7%
Beta vs S&P 500, 1Y 2.070.680.76 1.00
Return / volatility, 1Y -0.391.221.67 0.97
Max drawdown, 5Y -91.9%-61.1%-85.5% -25.4%
From 52-week high -69.9%-0.9%-0.5% -1.2%
52-week high $1.53$94.13$13.81 $779.14
52-week low $0.39$61.49$5.70 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGELSIFFOGN
P/E now vs peer median —median 32.1x 34.2xmedian 22.0x 17.3xmedian 17.2x
P/S now vs peer median —median 2.6x 2.4xmedian 1.4x 0.6xmedian 9.0x
EV/EBITDA now vs peer median —median 38.1x 17.0xmedian 12.4x 7.5xmedian 16.3x
P/FCF now vs peer median -6.9xmedian 21.5x 44.1xmedian 15.1x 6.4xmedian 18.7x
P/B now vs peer median 0.5xmedian 3.1x 1.7xmedian 1.6x 3.6xmedian 2.2x
PEG now vs peer median —median 2.03 1.06median 1.66 -0.48median 0.33

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGELSIFFOGN
Revenue – $9.98B $6.13B
Gross profit – $3.74B $3.23B
Operating income – $754.00M $1.13B
Net income – $295.00M $209.00M
Free cash flow – $540.00M $567.00M
R&D – $684.00M $358.00M
EPS (diluted) – $2.71 $0.77
Cash & equivalents $6.26K $569.00M $1.13B
Total debt $8.91M $5.70B $8.55B
Shares (diluted) 9.27M 257.00M 270.45M
Enterprise value $2.78M $21.50B $114.25M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGELSIFFOGN
P/E – 34.2x 17.3x
P/FCF -6.9x 44.1x 6.4x
P/Operating cash flow – 20.5x 4.9x
P/S – 2.4x 0.6x
P/B 0.5x 1.7x 3.6x
P/Tangible book -1.4x 2.3x -34.0x
EV/EBITDA – 17.0x 7.5x
EV/EBIT – 38.4x 9.8x
EV/Revenue – 2.9x 1.8x
EV/FCF – 53.6x 19.5x
EV/Operating cash flow – 24.9x 15.0x
PEG (3Y EPS CAGR) – 1.06 -0.48

Growth

14 metrics
MetricGELSIFFOGN
Revenue growth (1Y) – -4.6% -2.5%
Revenue CAGR (3Y) – -5.6% -0.2%
Gross profit growth (1Y) – -3.8% -8.7%
Gross profit CAGR (3Y) – -0.2% -5.3%
Operating income growth (1Y) – 295.8% -9.3%
Operating income CAGR (3Y) – 35.2% -8.1%
Net income growth (1Y) – 170.2% -70.1%
Net income CAGR (3Y) – 28.8% -34.8%
EPS growth (1Y) – 900.0% -71.3%
EPS CAGR (3Y) – 32.3% -36.0%
Operating cash flow growth (1Y) – 5.4% -10.8%
Operating cash flow CAGR (3Y) – 12.2% 0.5%
Free cash flow growth (1Y) – -4.4% -13.8%
Free cash flow CAGR (3Y) – 26.8% 5.0%

Profitability

14 metrics
MetricGELSIFFOGN
Gross margin – 37.5% 52.7%
EBITDA margin – 17.1% 24.2%
Operating margin – 7.6% 18.4%
Pretax margin – 3.5% 8.0%
Net margin – 7.0% 3.4%
FCF margin – 5.4% 9.3%
Operating cash flow margin – 11.6% 12.0%
Return on equity – 2.1% 21.9%
Return on assets – 1.2% 1.6%
Return on invested capital – 3.0% 5.0%
Return on capital employed – 3.6% 10.8%
Asset turnover – 0.4x 0.5x
Cash conversion (OCF / net income) – 3.9x 3.5x
Stock comp / revenue – 0.9% 1.2%

Financial Health

11 metrics
MetricGELSIFFOGN
Debt / assets 0.1% 22.7% 64.9%
Debt / equity 0.0x 0.4x 8.5x
Net debt / EBITDA – 3.0x 5.0x
Debt / FCF – 10.6x 15.1x
Liabilities / assets 29.4% 44.3% 92.4%
Equity / assets 70.6% 55.7% 7.6%
Interest coverage – 4.0x 2.4x
Current ratio 0.1x 2.1x 2.0x
Quick ratio 0.1x 0.5x 1.0x
Cash ratio 0.0x 0.1x 0.4x
Altman Z-score – 1.81 1.30

Shareholder Returns

7 metrics
MetricGELSIFFOGN
Dividend yield – 1.7% 0.6%
Net buyback yield – 0.3% –
Shareholder yield – 2.0% 0.6%
Payout ratio (earnings) – 138.6% –
Payout ratio (FCF) – 75.7% –
Dividend growth (1Y) – 0.0% –
Dividend CAGR (3Y) – -20.7% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGELSIFFOGN
Forward P/E – 28.4xFY2026 3.9xFY2026
EPS, next fiscal year – $3.28FY2026 $3.56FY2026
EPS growth, next FY – -21.9%FY2026 -2.7%FY2026
EPS growth, the year after – +23.5% 0.0%
Revenue, next fiscal year – $8.10BFY2026 $5.89BFY2026
Revenue growth, next FY – -25.7%FY2026 -5.3%FY2026
Revenue growth, the year after – -8.1% +3.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGELSIFFOGN
Held by institutions – 100.0% 84.3%
Institutions holding – 753 631
Change in shares held, QoQ – +6.0% +10.8%
Institutions buying – 410 244
Institutions selling – 226 186
Buyers to sellers – 1.81 1.31

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GELSIFFOGN
GELS 1.00 0.03 0.04
IFF 0.03 1.00 0.06
OGN 0.04 0.06 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GELS, IFF and OGN?

International Flavors & Fragrances (IFF) is the largest by market capitalisation: Gelteq (GELS) $4.93M, International Flavors & Fragrances (IFF) $23.80B, Organon (OGN) $3.61B.

Which stock is cheaper, GELS, IFF and OGN?

Organon (OGN) trades on the lowest price-to-earnings ratio (International Flavors & Fragrances (IFF) 34.2x, Organon (OGN) 17.3x). On next year's consensus earnings, Organon (OGN) is cheapest (International Flavors & Fragrances (IFF) 28.4x, Organon (OGN) 3.9x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Organon (OGN) grew revenue fastest over the trailing twelve months: International Flavors & Fragrances (IFF) -4.6%, Organon (OGN) -2.5%.

Which company is more profitable?

International Flavors & Fragrances (IFF) has the highest net margin (International Flavors & Fragrances (IFF) 7.0%, Organon (OGN) 3.4%). On return on invested capital, Organon (OGN) leads (International Flavors & Fragrances (IFF) 3.0%, Organon (OGN) 5.0%).

Which stock has performed better?

Over the past year Organon (OGN) returned the most: Gelteq (GELS) -62.0%, International Flavors & Fragrances (IFF) +42.8%, Organon (OGN) +94.6%. Over five years, International Flavors & Fragrances (IFF) compounded fastest (International Flavors & Fragrances (IFF) -8.9%/yr, Organon (OGN) -17.8%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

International Flavors & Fragrances (IFF) has the highest dividend yield: International Flavors & Fragrances (IFF) 1.72%, Organon (OGN) 0.58%. Gelteq (GELS) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, International Flavors & Fragrances (IFF) has been the steadiest (Gelteq (GELS) 159.5%, International Flavors & Fragrances (IFF) 35.0%, Organon (OGN) 56.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GELS, IFF and OGN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, International Flavors & Fragrances (IFF) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.